Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.

Yushan Pan Waseem AhmedPrerna MahtaniRochelle WongRandy LongmanDana Jeremy LukinEllen J ScherlRobert Battat

Published in: Inflammatory bowel diseases (2022)

In POCD, established anti-tumor necrosis factor concentrations were associated with improved outcomes. No relationship between UST concentrations and postoperative outcomes existed.

Keyphrases

patients undergoing
rheumatoid arthritis
metabolic syndrome
adipose tissue
insulin resistance